AVICANNA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.36 CAD | +5.88% |
|
-11.11% | +2.86% |
| 19/04 | Avicanna Raises About $2.1 Million in Non-brokered Private Placement | MT |
| 18/04 | Avicanna Inc. announced that it has received CAD 2.125584 million in funding | CI |
| Sales 2022 | 4.05M 2.96M 247M | Sales 2023 | 16.79M 12.27M 1.02B | Capitalization | 31.74M 23.2M 1.94B |
|---|---|---|---|---|---|
| Net income 2022 | -14M -10.23M -854M | Net income 2023 | -8M -5.85M -488M | EV / Sales 2022 | 8.09 x |
| Net Debt 2022 | 2.02M 1.47M 123M | Net Debt 2023 | 1.33M 969K 80.88M | EV / Sales 2023 | 1.97 x |
| P/E ratio 2022 |
-1.65
x | P/E ratio 2023 |
-3.39
x | Employees | 87 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 82.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Avicanna Inc.
More press releases
More news
| 1 day | +5.88% | ||
| 1 week | -11.11% | ||
| Current month | -30.77% | ||
| 1 month | -32.08% | ||
| 3 months | +20.00% | ||
| 6 months | -10.00% | ||
| Current year | +2.86% |
1 week
0.33
0.41
1 month
0.320.55
Current year
0.300.60
1 year
0.230.60
3 years
0.161.16
5 years
0.167.40
10 years
0.167.40
| Managers | Title | Age | Since |
|---|---|---|---|
Aras Azadian
FOU | Founder | 37 | 01/15/01 |
Phillip Cardella
DFI | Director of Finance/CFO | - | - |
Karolina Urban
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Fornazzari
BRD | Director/Board Member | 57 | 13/11 |
Aras Azadian
FOU | Founder | 37 | 01/15/01 |
John McVicar
BRD | Director/Board Member | - | 24/21/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.36 | +5.88% | 133,030 |
| 25/24/25 | 0.34 | -10.53% | 259,527 |
| 24/24/24 | 0.38 | -2.56% | 57,940 |
| 23/24/23 | 0.39 | +2.63% | 28,500 |
| 22/24/22 | 0.38 | -6.17% | 216,921 |
Delayed Quote Toronto S.E., April 27, 2024 at 01:27 am IST
More quotes
Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patientsâ needs and enhances the patient's journey.
Calendar
27/05/2024
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +2.86% | 25.67M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AVCN Stock
